 Home > Medical News >

Medical Research Articles

Regenerative meta-eye injection Eylea (aflibercept) yielded positive results in phase 3 trial PANORAMA

 Time of Update: 2020-06-11

blocking factor proliferation phase aqua phase vascular endothelial growth factor bx795 clinical trials

recently, Regeneration announced that the company (which has been by the FDA (approved vascular endothelial growth factor (VEGF) inhibitor eye injection Eylea (aflibercept) and that the drug (
FDA approves XEOMIN ®'s application for license for complementary biologics

 Time of Update: 2020-06-11

fda biocompatibility guidance botox global company list fei number fda common eating disorders

salivating is a common symptom in patients with neurological disorders including Parkinson's disease, amyotrophic lateral sclerosis, cerebral palsy or stroke This symptom may occur due to difficulti
Roche Cancer Immunotherapy Tecentriq II Clinical Study IMpassion130 Reaches Major Endpoint

 Time of Update: 2020-06-11

new world cleaners benadryl drug world food xanax drug effects food safety definition

recently, Swiss Pharmaceuticals (Roche) announced that iMpassion130, a phase III clinical study of the evaluation of the cancer immunotherapy tecentriq (TNBC) first-line chemotherapy treatment, ha
Palynziq injections obtain FDA standard approval for PKU adult patients

 Time of Update: 2020-06-11

prednisone 20 mg strattera 40 mg double 3 4 nexium 40 mg nadolol 20 mg

PKU is a rare genetic disease that manifests itself at birth and can lead to various cumulative toxicity to the brain recently, BioMarin Pharmaceutical announced that the Palynziq (pegvaliase-pqpz)
FD grants STRO-001 orphan drug for multiple myeloma

 Time of Update: 2020-06-11

cardiac muscle cell mmp protein immuno oncology drugs tertiary structure protein _____what cell proliferation

recently, Sutro Biopharma (announced that the U.S Food and Drug ( FDA ( ) has granted STRO-001 the right to treat multiple myeloma (MM) orphan drugs STRO-001 is a potentially first-of-its-kind
New Key announces positive results for new drug Revlidomide in Phase 3 clinical trial OF EM

 Time of Update: 2020-06-11

new customer burkitt's non hodgkin's lymphoma used role new bharat transport new na

inert lymphoma refers to slow-spreadly lymphoma, a non-Hodgkin's lymphoma (NHL) type that accounts for about 40 percent of the NHL recently, , a new company, announced positive results from the n
Study finds that a drug used to treat alcoholism XR-Naltrexone may be used to suppress HIV levels

 Time of Update: 2020-06-11

drugs similar gabapentin number 1 diesel naloxone hcl injection asl 1 100 50 50 alcohol

Recently, researchers at Yale University in the United States published a study (INSPIRE) in the Journal of AIDS (INSPIRE) showing that a FDA (approved for the treatment of alcohol-related drug (
FDA approves Pfizer's new cancer drug Talazoparib for treatment of breast cancer patients

 Time of Update: 2020-06-11

infigratinib fda approval dog dna results 1 2 bh 1 2 1 ratio omega 3 6 ratio

breast cancer is one of the most important types of cancer that threaten a woman's life Women who carry genetic BRCA1 or BRCA2 mutations have a 65 percent risk of developing breast cancer before age
Key Phase III clinical study of Therapy Keytruda, Amesa East PD-1 immunotherapy, reaches the main end of total survival

 Time of Update: 2020-06-11

spinocerebellar ataxia treatment palmar hyperhidrosis treatment pd disorder sewage water treatment hiv injection treatment

recently, Mercadon announced that pD-1 immunotherapy Keytruda (pembrolizumab) single-drug first-line treatment of tumor cell expression PD-L1 (combined ratio score of 20) recurrent or metastatic hea
European Commission approves Pfizer's quto-bead monobiosimilar Trazimera for treatment of stomach cancer

 Time of Update: 2020-06-11

celebrex generic name lotensin generic name tamiflu generic name depakote brand name cyclobenzaprine brand name

, the European Commission (EC) has approved trazimera, an anti-biosimilar, for treatment of HER2-positive breast cancer and HER2-positive metastatic stomach cancer or esophageal esophageal adenocarci
FDA approves Cinryze for the prevention of disease in patients with hereditary vascular edema in children 6 years and older

 Time of Update: 2020-06-11

1 3 dichloropropene terlipressin fda approval phentermine fda approved clinical research intern 3 en 1

recently, the United States The FDA (approved shire) company (Cinryze (C1 esterase inhibitor) for the prevention of disease in children 6 years and older with hereditary angioedema (HAE) it is
FDA approves Jansen prescription drug Xarelto (rivaroxaban) for reduced primary cardiovascular risk in CAD or PAD patients

 Time of Update: 2020-06-11

phenylephrine 5 mg calcort 6 mg phase 4 clinical trial effects vegetarianism body blood clots urine

chronic CAD and PAD are caused by hardening or stenosis caused by cholesterol and platelet build-up, which can disrupt blood circulation and, in severe cases, damage to limbs and vital organs such a
Novartis CAR-T cell therapy Kymriah approved for 2 B-cell malignancies

 Time of Update: 2020-06-11

cell cell lymphoma corporations united states fda gene therapy multi year planner world's largest chair

Recently, the European Medicines (EMA) Medicines ( CHMP) has issued a positive opinion recommending the approval of Novartis CAR-T cell therapy Kymriah for 2 Types of B-cell malignancies the t
FDA has granted Fibrocell its drug FCX-013 a quick-track determination for treatment of moderate to severe lysed disease

 Time of Update: 2020-06-11

bisacodyl uses acetylcholine uses fda approved gene therapy qpcr gene expression phase 100

Recently, Fibrocell Science Bio (announced) that the U.S FDA (which has been awarded to the company's clinical development phase candidate drug (a quick-track identification for the treatment
Sage Therapeutics Zulresso treatment of PPD has good risk benefits

 Time of Update: 2020-06-11

safety engineer salary rapid drug screen soliris drug zyrtec drug interactions cyclobenzaprine drug test

PPD is a clear and easily identifiable form of severe depression, a common birth complication that affects some pregnant women and usually occurs late in pregnancy or within 4 weeks of childbirth r
FDA grants Aravive's fast-track eligibility for a research drug AVB-S6-500

 Time of Update: 2020-06-11

protein production high cell identity markers cell markers indianapolis 500 track protein synthesis activity

recently, the Houston Aravive Bio Medicines (The Company (announced that the FDA (which has been granted the of the drug (fast-track eligibility) for the treatment of recurrent ovarian cancer
Motif Bio submits new drug application to U.S. FDA

 Time of Update: 2020-06-11

new fda approvals fast cure epoxy broad spectrum concrete antibacterial double 3 4

recently, antibiotics new drug (Research and Company (Bio) announced that it has submitted a new drug application (NDA) to the U.S FDA (NDA) for the treatment of acute bacterial skin and skin s
FDA grants lurbinectin (PM1183) orphan drug title

 Time of Update: 2020-06-11

1 3 dichlorobenzene yellow number 1 nyc drug delivery oxybutynin 5 mg asap drug testing

recently, the U.S Food and Drug ( FDA ( FDA) awarded the title of lurbinectedin (PM1183) orphan drug, data show that the drug treatment after chemotherapy progress small cell lung cancer (SCLC)
Foamix foam preparation FMX103 treatment of severe papules pustules acne reaches two major therapeutic endpoints

 Time of Update: 2020-06-11

blastomycosis skin lesions phase metabolism jp 5 0 quality life supplements bio oil results

papules pustules acne is a chronic skin disease that causes inflammatory lesions (pimpand and pustules) on the nose, cheeks, chin and forehead that can cause socio-psychological burdens such as dist
FDA accepts additional listing application from Boxei Spree (dasatinib)

 Time of Update: 2020-06-11

philadelphia chromosome leukemia december 29 birthstone all natural moisturizer what tyrosine kinase libtayo fda approval

Ph-ALL is a rare subtype of ALL, a common childhood cancer, accounting for about 3-4% of all children with ALL The difference between Ph-ALL and standard ALL is that a mutation carried by a patient

Go to Page

Medical Research Articles

Regenerative meta-eye injection Eylea (aflibercept) yielded positive results in phase 3 trial PANORAMA

FDA approves XEOMIN ®'s application for license for complementary biologics

Roche Cancer Immunotherapy Tecentriq II Clinical Study IMpassion130 Reaches Major Endpoint

Palynziq injections obtain FDA standard approval for PKU adult patients

FD grants STRO-001 orphan drug for multiple myeloma

New Key announces positive results for new drug Revlidomide in Phase 3 clinical trial OF EM

Study finds that a drug used to treat alcoholism XR-Naltrexone may be used to suppress HIV levels

FDA approves Pfizer's new cancer drug Talazoparib for treatment of breast cancer patients

Key Phase III clinical study of Therapy Keytruda, Amesa East PD-1 immunotherapy, reaches the main end of total survival

European Commission approves Pfizer's quto-bead monobiosimilar Trazimera for treatment of stomach cancer

FDA approves Cinryze for the prevention of disease in patients with hereditary vascular edema in children 6 years and older

FDA approves Jansen prescription drug Xarelto (rivaroxaban) for reduced primary cardiovascular risk in CAD or PAD patients

Novartis CAR-T cell therapy Kymriah approved for 2 B-cell malignancies

FDA has granted Fibrocell its drug FCX-013 a quick-track determination for treatment of moderate to severe lysed disease

Sage Therapeutics Zulresso treatment of PPD has good risk benefits

FDA grants Aravive's fast-track eligibility for a research drug AVB-S6-500

Motif Bio submits new drug application to U.S. FDA

FDA grants lurbinectin (PM1183) orphan drug title

Foamix foam preparation FMX103 treatment of severe papules pustules acne reaches two major therapeutic endpoints

FDA accepts additional listing application from Boxei Spree (dasatinib)